| Source: |
| Type: |
| SUV39H1/KMT1A (suppressor of variegation 3-9 homolog 1; H3K9 histone methyltransferase) is a SET-domain lysine methyltransferase that catalyzes methylation of histone H3 lysine 9, particularly formation of H3K9me3, a repressive chromatin mark associated with heterochromatin and transcriptional silencing. SUV39H1 regulates chromatin organization, genome stability, cellular differentiation, senescence and gene expression. In several cancers, increased SUV39H1 activity can promote epigenetic silencing of tumour-suppressive genes, stemness, proliferation and treatment resistance, although its role can vary by tumour context. In such settings, the cancer-associated direction is commonly up and the desired anticancer modulation is down or methyltransferase inhibition. |
| Acute Myeloid Leukemia |
| 7183- | CHA, | The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | AML, | KG-1 | - | in-vitro, | lymphoma, | U937 |
| 7186- | CHA, | TSA, | Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A |
| - | in-vitro, | AML, | NA |
| 7166- | CHA, | Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1 |
| - | vitro+vivo, | AML, | U937 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:2 Cells:% prod#:% Target#:1592 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid